The Newsroom

Investigations  /  11.27.2019

Investigation of Aclaris Therapeutics

You Have Legal Options

Aclaris Therapeutics (ACRS) Accused of Making Misleading Claims Regarding its ESKATA Drug

According to the complaint against the company’s officers and directors for breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and alleged violations of the Securities Exchange Act of 1934 from May 8, 2018 through the present, Aclaris Therapeutics (ACRS) announced the launch of ESKATA, touting the product as the “first and only FDA-approved topical treatment for seborrheic keratosis.” Despite positive expectations, Aclaris acknowledged in its 2017 10-K that ESKATA was subject to post-marketing restrictions and that failure to comply with regulations could lead to penalties. Despite these warnings, Aclaris’ officers and directors allowed advertisements for ESKATA that exaggerated the drug’s efficacy and understated its risks. Consequently, on June 20, 2019, the FDA issued a letter expressing concern over misleading statements and omissions in Aclaris’ advertising regarding ESKATA’s efficacy and risk of harmful side effects, noting that the company was previously warned about the consequences of these advertising defects prior to publishing. As a result of Aclaris’ officers and directors’ failure to prevent the dissemination of false information, Aclaris, its CEO, and its CFO have been named in two federal securities class actions, which could further deplete the company’s assets. Since this news, Aclaris’ share price has fallen $3.41, an almost 67% decline from its June 19, 2019 closing price of $5.11.

  • If you would like more information about your rights and potential remedies please send us a message. 

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns